Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
By J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian, P. Hwu, Charles G. Drake, L. Camacho, J. Kauh, K. Odunsi and 16 more. New England Journal of Medicine, 2012
7,418 citations recorded by the source corpus.
BACKGROUND Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host’s immune system. Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models. METHODS In this multicenter phase 1 trial, we administered intravenous anti–PD-L1 antibody (at escalating doses ranging from 0.3 to 10 mg per kilogram of body weight) to patients with selected advanced cancers. Anti–PD-L1 antibody was administered every 14 days in 6-week cycles for up to 16 cycles or until the patient had a complete response or confirmed disease progression. RESULTS As of February 24, 2012, a total of 207 patients — 75 with non–small-cell lung cancer, 55 with melanoma, 18 with colorectal cancer, 17 with renal-cell cancer, 17 with ovarian cancer, 14 with pancreatic cancer, 7 with gastric cancer, and 4 with breast cancer — had received anti–PD-L1 antibody. The median duration of therapy was 12 weeks (range, 2 to 111). Grade 3 or 4 toxic effects that investigators considered to be related to treatment occurred in 9% of patients. Among patients with a response that could be evaluated, an objective response (a complete or partial response) was observed in 9 of 52 patients with melanoma, 2 of 17 with renal-cell cancer, 5 of 49 with non–small-cell lung cancer, and 1 of 17 with ovarian cancer. Responses lasted for 1 year or more in 8 of 16 patients with at least 1 year of follow-up. CONCLUSIONS Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks) in patients with advanced cancers, including non–small-cell lung cancer, melanoma, and renal-cell cancer. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00729664.)
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/b5af1c3cbcdcf2f227adbd0e23f393e9b42208f5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Lieping Chen
- D. Pardoll
- S. Rosenberg
- J. Wolchok
- James P. Allison
- M. Smyth
- E. Wherry
- Ton N. Schumacher
In Oncology
- J. Wolchok
- Lieping Chen
- S. Rosenberg
- D. Pardoll
- James P. Allison
- Ton N. Schumacher
- E. Wherry
- M. Smyth
Citations in the corpus
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation (2014, background): “, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
- PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies (2013, neutral): “have resulted in durable clinical responses in patients with non–small cell lung cancer, renal cell cancer, and melanoma (3, 4).”
- Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2015, neutral): “IRF7 is frequently promoter DNA hypermethylated in cancer and the associated low basal expression can be reversed by Aza in squamous NSCLC (Wrangle et al., 2013).”
- Overcoming T cell exhaustion in infection and cancer (2015, background): “the majority of patients still fail to achieve robust objective clinical responses [21-23, 25-32].”
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, background): “IRAEs are frequent; they occur in up to 90% of patients treated with an anti-CTLA-4 antibody [2] and 70% of patients treated with an PD-1/PD-L1 antibody [11,17].”
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018, background): “MSI cases show improved response to immune checkpoint therapy, independent of histology (Brahmer et al., 2012; Gryfe et al., 2000; Le et al., 2015).”
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints (2016, background): “Importantly, (1) elevation of TIM-3 expression in T cells was predominantly found on the therapeutic PD-1 antibody-bound subset, (2) upregulation of TIM-3 was only detected in tumour-bearing lungs but not in sentinel lymph nodes and peripheral blood, (3) TIM-3 positivity was significantly correlated”